Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 525 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Why ASCO’s Annual Meeting Matters for People With Cancer and How... June 1, 2021 COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... September 13, 2020 Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... September 21, 2020 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... February 3, 2022 Load more HOT NEWS New on NCI’s Websites for March 2025 What Is Mindfulness and How Can It Help People With Cancer? Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... Quitting Smoking Improves Survival in People with Lung Cancer
